Vigil Neuroscience, Inc. (VIGL) |
|
6.48 0.41 (6.75%)
|
09-27 16:00 |
|
Open: |
6.07 |
Pre. Close: |
6.07 |
|
High:
|
6.61 |
Low:
|
5.7556 |
|
Volume:
|
22,865 |
Market Cap:
|
232(M) |
|
|
|
Technical analysis |
as of: 2023-09-27 4:22:52 PM |
|
Short-term rate:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 8.73 One year: 10.2 |
| Support: |
Support1: 5.75 Support2: 4.68 |
| Resistance: |
Resistance1: 7.48 Resistance2: 8.73 |
| Pivot: |
5.85 |
| Moving Average: |
MA(5): 5.88 MA(20): 5.87 
MA(100): 7.96 MA(250): 9.99 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 55.6 %D(3): 45.1 |
| RSI: |
RSI(14): 53 |
| 52-week: |
High: 16.77 Low: 4.68 |
| Average Vol(K): |
3-Month: 50 (K) 10-Days: 50 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ VIGL ] has closed below upper band by 27.8%. Bollinger Bands are 19.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
6.61 - 6.63 |
6.63 - 6.65 |
|
Low:
|
5.7 - 5.72 |
5.72 - 5.75 |
|
Close:
|
6.43 - 6.47 |
6.47 - 6.51 |
|
Company Description |
|
Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts. |
Headline News |
Tue, 26 Sep 2023
Vigil Neuroscience Receives Positive Opinion from European Medicines Agency on Orphan Drug Designation for VGL101 for the Treatment of ALSP - Yahoo Finance
Wed, 13 Sep 2023
Healthcare Stocks on the Move Wednesday: RCKT, AWH, VIGL, CDXS, HOTH, YCBD, FLGC, CELZ - InvestorsObserver
Wed, 13 Sep 2023
What is the Market's View on Vigil Neuroscience Inc (VIGL) Stock's Price and Volume Trends Wednesday? - InvestorsObserver
Fri, 08 Sep 2023
Vigil Neuroscience Announces Update on its Small Molecule ... - GlobeNewswire
Tue, 08 Aug 2023
Vigil Neuroscience Reports Second Quarter 2023 Financial Results ... - GlobeNewswire
Mon, 07 Aug 2023
Vigil Neuroscience Appoints Christopher J. Silber, M.D. as - GlobeNewswire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
36 (M) |
| Shares Float |
9 (M) |
|
% Held by Insiders
|
10.1 (%) |
|
% Held by Institutions
|
88.8 (%) |
|
Shares Short
|
786 (K) |
|
Shares Short P.Month
|
548 (K) |
Stock Financials |
|
EPS
|
-1.73 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
4.28 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-29.8 |
|
Return on Equity (ttm)
|
-49.9 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-2.21 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-71 (M) |
|
Levered Free Cash Flow
|
-42 (M) |
Stock Valuations |
|
PE Ratio
|
-3.77 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
1.51 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-3.3 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
